Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Iopromide
Drug ID BADD_D01182
Description Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the path of flow of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Available as the FDA-approved product Ultravist, iopromide is used in radiographic studies such as intra-arterial digital subtraction angiography (IA-DSA), cerebral and peripheral arteriography, peripheral venography, excretory urography, brain computer tomography (CT), coronary arteriography, left ventriculography, visceral angiography, and aortography.
Indications and Usage Contrast computed tomography (CT) imaging of head and body (300 mg I/mL and 370 mg I/mL)
Marketing Status Prescription; Discontinued
ATC Code V08AB05
DrugBank ID DB09156
KEGG ID D01893
MeSH ID C038192
PubChem ID 3736
TTD Drug ID D07GNP
NDC Product Code 50419-346; 50419-344
Synonyms iopromide | lopromid | N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-N-methylisophthalamide | iopromid | Ultravist 300 | Clarograf | Ultravist
Chemical Information
Molecular Formula C18H24I3N3O8
CAS Registry Number 73334-07-3
SMILES CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)NC(=O)COC)I
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Infusion site erythema23.03.06.016; 12.07.05.009; 08.02.05.008--Not Available
Hypoacusis04.02.01.006--
Brain oedema17.07.02.003; 12.01.10.010--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Infusion site pain12.07.05.002; 08.02.05.014--Not Available
Infusion site oedema08.02.05.012; 12.07.05.013--Not Available
Affect lability19.04.01.001--Not Available
Infusion site reaction12.07.05.006; 08.02.05.005--Not Available
Haemorrhage24.07.01.002--Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Vasodilation procedure25.03.01.001--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Infusion site rash23.03.13.018; 12.07.05.017; 08.02.05.017--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Infarction24.04.02.017--Not Available
Inflammation08.01.05.007--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Lacrimal disorder06.08.02.005--Not Available
Obstructive airways disorder22.03.01.011--Not Available
Renal impairment20.01.03.010--Not Available
Effusion08.01.03.052--Not Available
Anaphylactoid shock10.01.07.004; 24.06.02.005--Not Available
Body temperature fluctuation13.15.01.031--Not Available
Infusion site haematoma24.07.01.042; 12.07.05.001; 08.02.05.001--Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages